Publications
The cyclophilin inhibitor Debio 025 is a potent inhibitor of Hepatitis C virus replication in vitro and has unique resistance…
Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer
Evaluation of a cyclophilin inhibitor in Hepatitis C virus-infected chimeric mice in vivo
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer
Viral Kinetics During 14-day Treatment with Debio-025 Demonstrate Efficient Blocking of Viral Replication in Different HCV Genotypes without Signs of…
The Reduction of both Cyclophilin B and HCV-RNA by the Cyclophilin Inhibitor Debio-025 Confirms the Importance of Cyclophilin B for…
Low Risk of Drug Interaction between the Cyclophilin Inhibitor Debio-025 and (Peg) IFNa/ribavirin in HCV